News

22.01.2013

Strategic Alliance “Novel Targets for the Therapy of Obesity-Linked Diabetes”

27. Nov 2012
Sanofi and the Institute of Diabetes and Obesity (IDO) at Helmholtz Zentrum München have entered a new strategic research alliance in the field of diabetes and obesity research.

From 2013 on, the alliance “Novel Targets for the Therapy of Obesity-Linked Diabetes” will focus on the identification and validation of new targets and screening methods. Here new technologies shall be used for the development of innovative approaches to treat patients with diabetes and obesity. Another component of the strategic alliance will be an exchange program for scientists of the two partners.

The newly established institute at Helmholtz Zentrum München, which is a member of the initiative of the German Center for Diabetes Research, is directed by Matthias Tschöp, Alexander von Humboldt Professor and one of the most renowned experts in the field of diabetes and metabolic research. The advantages of the Institute include access to animal models and epidemiological cohort studies at Helmholtz Zentrum München as well as the participation of clinical cooperation partners. Thus, the Institute will create a unique environment for translational approaches in the field of diabetes research.

“We are delighted at the prospect of working with Professor Tschöp in target research,” said Philip Just Larsen, global head of research and translational medicine of the Diabetes Division at Sanofi. “Through the collaboration with Germany’s preeminent researcher in the field of energy homeostasis and obesity,” he added, “we hope to develop new treatments for patients with type 2 diabetes. We are confident that the combination of Professor Tschöp’s creative scientific approach and Sanofi’s extensive expertise in drug development are the key to achieving further pharmaceutical breakthroughs.” Matthias Tschöp emphasized the importance of the strategic alliance between Sanofi and diabetes research at Helmholtz-Zentrum München: “This alliance will facilitate the development of innovative targets for new drugs and treatment approaches for the benefit of diabetes patients. To achieve this, we have recruited an ambitious international research team, established state-of-the-art methodological approaches and can rely on Sanofi’s outstanding expertise in the field of pharmacological validation and molecular optimization.”

Both partners have agreed to launch two collaborative projects in which genome-wide RNAi screening will be used to identify metabolic pathways and new proteins that regulate energy homeostasis and to validate these in vivo.

Helmholtz Zentrum München and the Diabetes Division of Sanofi will complement each other by means of their unique expertise in target identification and validation as well as in the field of drug discovery and will benefit in equal measure from this partnership.

About Sanofi-Aventis Deutschland GmbH

The Sanofi-Aventis Deutschland GmbH is a company of the Sanofi group, a global leader in healthcare. Sanofi discovers, develops and distributes therapeutic solutions focused on patients‘ needs. The company has core strengths in healthcare, with 7 growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi’s shares are listed on the stock exchanges of Paris (EURONEXT: SAN) and New York (NYSE: SNY).

Forward-looking statements:

This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, business dealings, product development and potential, services as well as statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties. Many of these risks and uncertainties are difficult to predict and are in principle beyond the control of Sanofi and could cause actual results and developments to differ considerably from those expressed in or implied or projected by the forward-looking information and statements. These risks and uncertainties include, among other things, the following: uncertainties inherent in research and development, future clinical data and analyses, including post marketing; decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, medical device or biological application that may be filed for any such product candidates; decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates; the absence of guarantee that the product candidates, if approved, will be commercially successful;  the future approval and commercial success of therapeutic alternatives as well as the risks and uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements“ in Sanofi’s annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Scientific Contact
Dr. Annette Janz, Head, Innovation Management, Helmholtz Zentrum München – German Research Center for Environmental Health GmbH, T. +49-89-31874271,

Contact Sanofi
Jan Hempker, Sanofi – External Communications
T. +49 69 305 - 30165,